The system is currently being assessed for its use in stroke rehabilitation in the Phase 3 supplemental study 'E-FIT', involving 60 patients. The trial is expected to be complete in Q2 2018, allowing the Company to file for clearance of this indication.
In the past, the most common treatments for depression have been medication and/or psychotherapy. With TMS, psychotherapy is still encouraged because it can help people maintain mental health. However, unlike antidepressants, TMS has few if any side effects.